September 29, 2015
Allergan expects revenue greater than $8B
Allergan plc has updated its second-half 2015 continuing operations financial forecast. The forecast reflects adjustments for the upcoming expected discontinued operations
Pharmaceuticals, Biotechnology and Life Sciences
Category: Europe
September 28, 2015
Sanofi and Lilly end lawsuit and discontinue similar disputes worldwide
Eli Lilly has entered into a settlement agreement to resolve patent litigation with Sanofi regarding its insulin glargine product, Basaglar.
September 28, 2015
Cyramza Phase II study meets its primary endpoint
Phase II study of its Cyramza (ramucirumab) in combination with docetaxel met its primary endpoint, demonstrating a statistically significant increase in progression-free survival (PFS) for patients with locally advanced or metastatic urothelial carcinoma who failed prior platinum-based therapy.
September 28, 2015
Collagen Solutions sings deal with Yucel Medikal
Collagen Solutions plc, has announced that its subsidiary Collagen Solutions Inc. has signed a supply agreement with Turkish medical device company Yücel Medikal Ltd.
September 28, 2015
Afinitor (everolimus) tablets reduced the risk of progression of neuroendocrine tumors
Novartis has announced results of a Phase III pivotal study showing Afinitor (everolimus) tablets reduced the risk of progression by 52% vs placebo in patients with advanced, progressive, nonfunctional neuroendocrine tumors (NET) of gastrointestinal (GI) or lung origin.
September 26, 2015
Allergan Launches Generic Version of Invega
Allergan plc announced on Friday that it has launched a generic version of Janssen’s Invega (paliperidone extended-release tablets) in the…
September 26, 2015
Janssen’s daratumumab accepted for treatment of European patients with heavily pre-treated multiple myeloma
Janssen-Cilag International NV has announced on Friday that the Committee for Medicinal Products for Human Use (CHMP) of the European…
September 25, 2015
CHMP reccomends Bayer’s Eye medicine for approval in EU
The European Committee for Medicinal Products for Human Use (CHMP) has recommended Bayer’s aflibercept solution for injection into the eye…
September 25, 2015
Novartis: New NIBR director named. Entresto closer to be available EU
Switzerland-based Novartis has today appointed Dr. James E. Bradner, physician-scientist from Dana-Farber Cancer Institute and Harvard Medical School, as President of the…
September 25, 2015
‘Novartis Access’, a portfolio of affordable medicines to treat chronic diseases in lower-income countries
Novartis has announced the launch of Novartis Access, a portfolio of 15 medicines to treat chronic diseases in low- and…